Drug Profile
Research programme: nicotine receptor agonist - Endovasc
Alternative Names: Angiogenix; Nicotine receptor agonist-liposomal; NRALatest Information Update: 14 Jun 2005
Price :
$50
*
At a glance
- Originator Stanford University
- Developer HERMES BioSciences; Stentgenix
- Class
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cardiovascular disorders; Coronary artery restenosis; Heart failure; Peripheral arterial occlusive disorders
Most Recent Events
- 25 May 2005 Discontinued - Preclinical for Alzheimer's disease in Sweden (unspecified route)
- 25 May 2005 Discontinued - Preclinical for Cardiovascular disorders in USA (Parenteral)
- 25 May 2005 Discontinued - Preclinical for Coronary artery restenosis in USA (Implant)